AngioDynamics Historical Income Statement

ANGO Stock

USD 6.83 0.12 1.73%

Historical analysis of AngioDynamics income statement accounts such as Interest Expense of 1.7 M, Total Revenue of 246.7 M or Gross Profit of 131.3 M can show how well AngioDynamics performed in making a profits. Evaluating AngioDynamics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of AngioDynamics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining AngioDynamics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AngioDynamics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.

About AngioDynamics Income Statement Analysis

AngioDynamics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to AngioDynamics shareholders. The income statement also shows AngioDynamics investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

AngioDynamics Income Statement Chart

At this time, AngioDynamics' Interest Expense is very stable compared to the past year. As of the 25th of November 2024, Other Operating Expenses is likely to grow to about 521.2 M, while Depreciation And Amortization is likely to drop about 18.5 M.

Interest Expense Total Revenue Gross Profit Other Operating Expenses Research Development Reconciled Depreciation

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Total Revenue

Total revenue comprises all receipts AngioDynamics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of AngioDynamics minus its cost of goods sold. It is profit before AngioDynamics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of AngioDynamics. It is also known as AngioDynamics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from AngioDynamics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into AngioDynamics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.At this time, AngioDynamics' Interest Expense is very stable compared to the past year. As of the 25th of November 2024, Other Operating Expenses is likely to grow to about 521.2 M, while Depreciation And Amortization is likely to drop about 18.5 M.

	2021	2022	2023	2024 (projected)
Gross Profit	165.7M	174.2M	154.7M	131.3M
Total Revenue	316.2M	338.8M	303.9M	246.7M

Gross Profit Total Revenue

AngioDynamics income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Tax Provision	Net Interest Income	Interest Income	Discontinued Operations	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.52	0.83	0.8	0.56	0.02	0.0	0.78	0.17	0.84	0.8	0.01	-0.01	-0.01	0.14	0.78	0.84	-0.02	-0.18	0.0	0.2	0.02	-0.2	0.24	0.32	0.36
Interest Expense	0.52		0.7	0.64	0.32	0.39	0.67	0.28	0.77	0.73	0.27	0.44	0.21	0.42	0.23	0.14	0.32	0.33	-0.77	-0.3	0.18	-0.51	0.57	-0.25	-0.18	-0.23
Total Revenue	0.83	0.7		0.99	0.65	0.17	0.32	0.8	0.46	0.99	0.77	0.17	0.05	0.15	0.18	0.64	0.83	0.12	-0.37	-0.13	0.21	-0.13	0.08	0.05	0.05	0.13
Gross Profit	0.8	0.64	0.99		0.65	0.16	0.29	0.85	0.43	0.96	0.79	0.13	-0.01	0.11	0.13	0.68	0.85	0.08	-0.3	-0.05	0.16	-0.1	0.04	0.13	0.06	0.21
Other Operating Expenses	0.56	0.32	0.65	0.65		-0.61	-0.29	0.66	-0.16	0.63	0.77	-0.51	-0.4	-0.51	-0.08	0.67	0.8	-0.54	0.1	0.02	0.0	0.57	-0.41	0.53	0.47	0.38
Operating Income	0.02	0.39	0.17	0.16	-0.61		0.79	-0.12	0.77	0.18	-0.33	0.88	0.59	0.87	0.28	-0.3	-0.28	0.85	-0.57	-0.21	0.2	-0.91	0.71	-0.65	-0.59	-0.46
Ebit	0.0	0.67	0.32	0.29	-0.29	0.79		-0.14	0.98	0.34	-0.21	0.8	0.46	0.78	0.29	-0.34	-0.19	0.7	-0.81	-0.35	0.2	-0.88	0.94	-0.66	-0.58	-0.56
Research Development	0.78	0.28	0.8	0.85	0.66	-0.12	-0.14		0.0	0.74	0.9	-0.17	-0.19	-0.17	-0.07	0.86	0.89	-0.2	0.08	0.17	0.0	0.25	-0.36	0.48	0.24	0.57
Ebitda	0.17	0.77	0.46	0.43	-0.16	0.77	0.98	0.0		0.48	-0.08	0.78	0.44	0.75	0.31	-0.21	-0.04	0.67	-0.83	-0.35	0.23	-0.85	0.89	-0.6	-0.51	-0.5
Cost Of Revenue	0.84	0.73	0.99	0.96	0.63	0.18	0.34	0.74	0.48		0.74	0.21	0.11	0.18	0.23	0.59	0.8	0.17	-0.43	-0.2	0.25	-0.16	0.12	-0.03	0.04	0.04
Total Operating Expenses	0.8	0.27	0.77	0.79	0.77	-0.33	-0.21	0.9	-0.08	0.74		-0.33	-0.3	-0.34	-0.04	0.9	0.96	-0.36	0.12	0.15	0.03	0.36	-0.4	0.49	0.35	0.59
Income Before Tax	0.01	0.44	0.17	0.13	-0.51	0.88	0.8	-0.17	0.78	0.21	-0.33		0.87	0.99	0.26	-0.38	-0.27	0.96	-0.59	-0.63	0.18	-0.9	0.79	-0.65	-0.39	-0.49
Total Other Income Expense Net	-0.01	0.21	0.05	-0.01	-0.4	0.59	0.46	-0.19	0.44	0.11	-0.3	0.87		0.87	0.18	-0.37	-0.23	0.89	-0.34	-0.87	0.11	-0.61	0.53	-0.51	-0.08	-0.41
Net Income	-0.01	0.42	0.15	0.11	-0.51	0.87	0.78	-0.17	0.75	0.18	-0.34	0.99	0.87		0.11	-0.37	-0.28	0.97	-0.57	-0.63	0.03	-0.88	0.77	-0.6	-0.37	-0.45
Income Tax Expense	0.14	0.23	0.18	0.13	-0.08	0.28	0.29	-0.07	0.31	0.23	-0.04	0.26	0.18	0.11		-0.14	0.03	0.14	-0.24	-0.12	0.98	-0.32	0.29	-0.39	-0.21	-0.37
Selling General Administrative	0.78	0.14	0.64	0.68	0.67	-0.3	-0.34	0.86	-0.21	0.59	0.9	-0.38	-0.37	-0.37	-0.14		0.87	-0.42	0.34	0.32	-0.01	0.41	-0.54	0.7	0.44	0.79
Selling And Marketing Expenses	0.84	0.32	0.83	0.85	0.8	-0.28	-0.19	0.89	-0.04	0.8	0.96	-0.27	-0.23	-0.28	0.03	0.87		-0.29	0.1	0.08	0.1	0.31	-0.4	0.47	0.47	0.52
Net Income From Continuing Ops	-0.02	0.33	0.12	0.08	-0.54	0.85	0.7	-0.2	0.67	0.17	-0.36	0.96	0.89	0.97	0.14	-0.42	-0.29		-0.55	-0.64	0.05	-0.83	0.68	-0.71	-0.38	-0.56
Non Operating Income Net Other	-0.18	-0.77	-0.37	-0.3	0.1	-0.57	-0.81	0.08	-0.83	-0.43	0.12	-0.59	-0.34	-0.57	-0.24	0.34	0.1	-0.55		0.34	-0.12	0.67	-0.78	0.67	0.5	0.63
Non Recurring	0.0	-0.3	-0.13	-0.05	0.02	-0.21	-0.35	0.17	-0.35	-0.2	0.15	-0.63	-0.87	-0.63	-0.12	0.32	0.08	-0.64	0.34		-0.06	0.35	-0.46	0.38	-0.12	0.39
Tax Provision	0.2	0.18	0.21	0.16	0.0	0.2	0.2	0.0	0.23	0.25	0.03	0.18	0.11	0.03	0.98	-0.01	0.1	0.05	-0.12	-0.06		-0.22	0.18	-0.28	-0.14	-0.26
Net Interest Income	0.02	-0.51	-0.13	-0.1	0.57	-0.91	-0.88	0.25	-0.85	-0.16	0.36	-0.9	-0.61	-0.88	-0.32	0.41	0.31	-0.83	0.67	0.35	-0.22		-0.87	0.67	0.49	0.51
Interest Income	-0.2	0.57	0.08	0.04	-0.41	0.71	0.94	-0.36	0.89	0.12	-0.4	0.79	0.53	0.77	0.29	-0.54	-0.4	0.68	-0.78	-0.46	0.18	-0.87		-0.68	-0.6	-0.61
Discontinued Operations	0.24	-0.25	0.05	0.13	0.53	-0.65	-0.66	0.48	-0.6	-0.03	0.49	-0.65	-0.51	-0.6	-0.39	0.7	0.47	-0.71	0.67	0.38	-0.28	0.67	-0.68		0.67	0.93
Reconciled Depreciation	0.32	-0.18	0.05	0.06	0.47	-0.59	-0.58	0.24	-0.51	0.04	0.35	-0.39	-0.08	-0.37	-0.21	0.44	0.47	-0.38	0.5	-0.12	-0.14	0.49	-0.6	0.67		0.56
Extraordinary Items	0.36	-0.23	0.13	0.21	0.38	-0.46	-0.56	0.57	-0.5	0.04	0.59	-0.49	-0.41	-0.45	-0.37	0.79	0.52	-0.56	0.63	0.39	-0.26	0.51	-0.61	0.93	0.56

Click cells to compare fundamentals

AngioDynamics Account Relationship Matchups

AngioDynamics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	23.8M	26.3M	29.5M	33.2M	27.7M	18.5M
Interest Expense	907K	861K	688K	2.7M	1.6M	1.7M
Total Revenue	264.2M	291.0M	316.2M	338.8M	303.9M	246.7M
Gross Profit	150.3M	156.8M	165.7M	174.2M	154.7M	131.3M
Other Operating Expenses	278.2M	306.0M	334.4M	357.4M	496.3M	521.2M
Operating Income	(14.2M)	(14.9M)	(19.0M)	(19.2M)	(97.7M)	(92.8M)
Ebit	(14.2M)	(35.2M)	(18.4M)	(21.0M)	(42.0M)	(39.9M)
Research Development	29.7M	36.4M	30.7M	29.9M	31.5M	21.9M
Ebitda	9.6M	(8.9M)	11.1M	12.2M	(14.3M)	(13.6M)
Cost Of Revenue	113.9M	134.2M	150.5M	164.5M	149.2M	115.4M
Total Operating Expenses	164.3M	171.8M	183.9M	192.9M	252.4M	126.6M
Income Before Tax	(167.1M)	(36.1M)	(29.9M)	(54.4M)	(191.6M)	(182.1M)
Total Other Income Expense Net	(153.0M)	(4.5M)	(1.5M)	(35.2M)	(93.9M)	(89.2M)
Net Income	(165.8M)	(31.5M)	(26.5M)	(52.4M)	(184.3M)	(175.1M)
Income Tax Expense	(1.3M)	(4.5M)	(3.4M)	(2.0M)	(7.3M)	(6.9M)
Selling General Administrative	37.9M	35.9M	38.5M	40.0M	41.2M	28.3M
Net Income Applicable To Common Shares	(166.8M)	(31.5M)	(26.5M)	(52.4M)	(47.2M)	(44.8M)
Selling And Marketing Expenses	78.6M	81.3M	95.3M	104.2M	102.8M	75.9M
Net Income From Continuing Ops	(166.8M)	(31.5M)	(26.5M)	(52.4M)	(184.3M)	(175.1M)
Non Operating Income Net Other	(1.0M)	92K	(790K)	(554K)	(637.1K)	(669.0K)
Non Recurring	153.1M	20.3M	10.3M	32.5M	37.4M	30.9M
Tax Provision	(1.3M)	(4.5M)	(3.4M)	(2.0M)	(7.3M)	(6.9M)
Net Interest Income	(907K)	(861K)	(688K)	(2.7M)	1.6M	1.7M
Reconciled Depreciation	23.8M	25.9M	29.3M	30.9M	27.7M	29.1M

Pair Trading with AngioDynamics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AngioDynamics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AngioDynamics will appreciate offsetting losses from the drop in the long position's value.

Moving against AngioDynamics Stock

0.62	VMD	Viemed Healthcare	Pair Corr
0.51	CVS	CVS Health Corp Aggressive Push	Pair Corr

The ability to find closely correlated positions to AngioDynamics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AngioDynamics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AngioDynamics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AngioDynamics to buy it.

The correlation of AngioDynamics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AngioDynamics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AngioDynamics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for AngioDynamics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether AngioDynamics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AngioDynamics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Angiodynamics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Angiodynamics Stock:

How To Invest In AngioDynamics

Details

Is AngioDynamics Stock a good investment?

Details

What is AngioDynamics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.

You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.05)

Revenue Per Share

7.249

Quarterly Revenue Growth

(0.14)

Return On Assets

(0.06)

Return On Equity

(0.78)

The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AngioDynamics Historical Income Statement

About AngioDynamics Income Statement Analysis

AngioDynamics Income Statement Chart

Interest Expense

Total Revenue

Gross Profit

Other Operating Expenses

AngioDynamics income statement Correlations

AngioDynamics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AngioDynamics income statement Accounts

Pair Trading with AngioDynamics

Moving against AngioDynamics Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 0.99	Total Revenue
Cost Of Revenue	+ 0.99	Total Revenue
Net Income	+ 0.99	Income Before Tax
Ebitda	+ 0.98	Ebit
Tax Provision	+ 0.98	Income Tax Expense
Net Income From Continuing Ops	+ 0.97	Net Income

Net Interest Income	- 0.91	Operating Income
Net Interest Income	- 0.9	Income Before Tax
Net Interest Income	- 0.88	Net Income
Net Interest Income	- 0.88	Ebit
Interest Income	- 0.87	Net Interest Income
Non Recurring	- 0.87	Total Other Income Expense Net